Protease Inhibitor [EPC]

44461 reported adverse events

Drugs of this class: DARUNAVIR RITONAVIR LOPINAVIR AND RITONAVIR DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE RITONAVIR 100 MG

These side effects are most commonly reported by patients taking drugs of the Protease Inhibitor [EPC] class:

# Side effect Count
0 DRUG INTERACTION 3971
1 FOETAL EXPOSURE DURING PREGNANCY 3073
2 PAIN 2218
3 ANXIETY 2166
4 EMOTIONAL DISTRESS 1908
5 DEPRESSION 1859
6 RENAL FAILURE 1831
7 BONE DENSITY DECREASED 1807
8 NAUSEA 1800
9 DIARRHOEA 1785
See all common reactions for Protease Inhibitor [EPC]

Drugs of the Protease Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 116 0.8992
1 TOTAL LUNG CAPACITY INCREASED 103 0.3787
2 MITOCHONDRIAL TOXICITY 244 0.2972
3 LIPODYSTROPHY ACQUIRED 630 0.2965
4 IMMUNE RECONSTITUTION SYNDROME 338 0.2618
5 BONE DEMINERALISATION 272 0.2568
6 CUSHING'S SYNDROME 173 0.2489
7 TRISOMY 18 75 0.1969
8 ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME 102 0.1950
9 VIROLOGIC FAILURE 960 0.1783
See all enriched reactions for Protease Inhibitor [EPC]